N-methyl-N'-nitro-N-nitrosoguanidine-induced carcinogenesis: differential pattern of upper gastrointestinal tract tumours in Wistar rats after single or chronic oral doses.
Male Wistar rats were treated with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) either as a single dose of 50, 125 or 250 mg/kg given by gavage or via drinking water for 28 weeks at a concentration of 40, 80 or 160 micrograms/ml, in the case of the higher concentration reverting to 80 micrograms/ml after the first 8 weeks. The single dose regimen had no effect on water intake or body weight, but the chronic exposure led to a dose-dependent reduction in water intake that was paralleled by a slower weight gain, with the final body weights at approximately 90, 84 and 79% of the control weight values. The combined yield of benign and malignant tumours (79-100% of the animals treated) occurred in the forestomach in the case of the single doses, whereas the chronic exposure resulted in a maximum yield of tumours located in the pyloric region of the glandular stomach (64-100% of animals treated). The principal histological types of tumours induced were squamous cell papilloma and carcinoma in the forestomach and adenocarcinoma in the pylorus. There was a persistent, but low yield (25-30% of animals treated) of tumours in the jejunum, mainly adenocarcinoma, after administration via drinking water, whereas after single doses, multiple solitary cysts and cholangioma (30% and 25-70% respectively of the animals treated) were found in the liver. This report differs from earlier reports in that marked effects were noted on water consumption and body weight gain and that tumour induction can be achieved after much shorter periods of exposure than previously reported in the literature. These data confirm the tissue specificity of MNNG when given either as a single or chronic dose regimen and provide a suitable model for the investigation of the target cell specificity of tumour induction.
Zaidi
N H
NH
Cancer Research Campaign Department of Carcinogenesis, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
O'Connor
P J
PJ
Butler
W H
WH
D000230:Adenocarcinoma / Q000139:chemically induced / Q000473:pathology; D000236:Adenoma / Q000139:chemically induced / Q000473:pathology; D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D004334:Drug Administration Schedule; D004379:Duodenal Neoplasms / Q000139:chemically induced / Q000473:pathology; D005770:Gastrointestinal Neoplasms / Q000139:chemically induced* / Q000473:pathology; D007580:Jejunal Neoplasms / Q000139:chemically induced / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology; D008297:Male; D008769:Methylnitronitrosoguanidine / Q000008:administration & dosage / Q000633:toxicity; D011708:Pylorus / Q000187:drug effects / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013274:Stomach Neoplasms / Q000139:chemically induced / Q000473:pathology
D008769:Methylnitronitrosoguanidine